Drug-Induced Pancreatic Exocrine Dysfunction: Clinical Perspectives, Mechanisms, and Management

Abstract

Drug-induced pancreatic exocrine dysfunction (DIPED) represents a clinically significant but often under-recognized entity in gastroenterology. This review synthesizes current evidence regarding epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic approaches, and management strategies. We discuss the mechanistic underpinnings of DIPED, highlight drugs most frequently implicated, and offer practical guidance for clinicians. Recent advances in diagnostics and therapeutic interventions, as well as guideline recommendations, are critically appraised to inform best practices in patient care.

Introduction

Pancreatic exocrine dysfunction, characterized by insufficient secretion of digestive enzymes, leads to maldigestion and malnutrition. While chronic pancreatitis and cystic fibrosis are well-known etiologies, drug-induced pancreatic exocrine dysfunction has emerged as a clinically important yet frequently overlooked cause. With the expanding pharmacopeia and increased longevity of patients with chronic conditions, the burden of DIPED is poised to rise. Awareness of this condition, its risk factors, and evidence-based management is crucial for gastroenterologists, internists, and other healthcare providers.

Epidemiology / Disease Burden

The true prevalence of DIPED remains difficult to ascertain, primarily due to underdiagnosis, heterogeneity in clinical presentation, and lack of standardized reporting. However, studies estimate that medications may account for up to 2-5% of all cases of exocrine pancreatic insufficiency (EPI). DIPED is particularly relevant in elderly populations, oncology patients, and individuals with polypharmacy. The disease burden is amplified by the resultant malabsorption, weight loss, fat-soluble vitamin deficiencies, and impaired quality of life. In oncology, chemotherapy-induced pancreatic exocrine dysfunction may contribute to cancer cachexia and limit tolerance to treatment.

Pathophysiology

The mechanisms underlying DIPED are diverse and drug-specific. Cytotoxic agents such as azathioprine and L-asparaginase can cause direct acinar cell injury, leading to impaired enzyme synthesis and secretion. Some agents, including thiazide diuretics and valproic acid, provoke hypersensitivity reactions resulting in inflammatory infiltrates and ductal obstruction. Others, like octreotide and somatostatin analogs, exert inhibitory effects on pancreatic secretion via hormonal pathways. Chronic use of certain medications, such as opioids, may disrupt neural regulation of pancreatic secretion, compounding exocrine dysfunction. The varied mechanisms highlight the importance of a mechanism-based approach in clinical evaluation and management.

Risk Factors

Several risk factors modulate susceptibility to DIPED. Polypharmacy, particularly in elderly or multimorbid patients, increases cumulative risk. Pre-existing pancreatic disorders, diabetes mellitus, and chronic alcohol consumption may lower the threshold for drug-induced injury. Genetic predispositions, such as polymorphisms in detoxification enzymes, may also play a role. High-dose or prolonged exposure to known pancreatotoxic drugs significantly enhances risk, underscoring the need for vigilance in at-risk populations.

Clinical Features

DIPED typically presents insidiously, with symptoms ranging from mild steatorrhea and bloating to severe malnutrition and fat-soluble vitamin deficiencies. Weight loss, abdominal discomfort, and diarrhea are common. In oncology populations, DIPED may manifest as exacerbation of chemotherapy-induced gastrointestinal toxicity. Importantly, the onset may be delayed or masked by other comorbidities, making early recognition challenging. Clinical suspicion should be heightened in patients with unexplained gastrointestinal symptoms and recent exposure to high-risk drugs.

Diagnosis

Diagnosis of DIPED relies on a combination of clinical, laboratory, and imaging findings. Fecal elastase-1 is a sensitive non-invasive marker of pancreatic exocrine function, with levels below 200 μg/g suggestive of EPI. Direct pancreatic function tests, while more sensitive, are rarely performed outside specialized centers. Imaging modalities such as abdominal ultrasound, CT, or MRI may reveal structural changes but are less useful in pure exocrine dysfunction without overt pancreatitis. A thorough medication history is paramount to establishing causality, and drug withdrawal with subsequent clinical improvement can provide diagnostic confirmation.

Treatment & Management

Management of DIPED begins with identification and discontinuation of the offending drug, whenever feasible. Pancreatic enzyme replacement therapy (PERT) is the cornerstone of symptomatic management, effectively alleviating steatorrhea and improving nutritional status. Dosage should be individualized and titrated to symptom relief and normalization of nutritional markers. Supportive measures, including dietary counseling and supplementation of fat-soluble vitamins, are essential. In refractory cases or when drug discontinuation is not possible, optimization of PERT and close monitoring for complications are critical. Multidisciplinary care involving gastroenterologists, pharmacists, and dietitians enhances outcomes.

Recent Advances / Emerging Therapies

Recent advances in the understanding of DIPED have focused on improved diagnostics and novel therapeutic approaches. High-resolution imaging and non-invasive biomarkers, such as serum trypsinogen and chymotrypsin-like elastase, offer promise for earlier detection. Advances in pharmaceutical formulation have led to more effective and patient-friendly enzyme replacement products. Experimental therapies targeting pancreatic regeneration and immune modulation are under investigation. Furthermore, pharmacogenomics may soon enable identification of individuals at heightened risk, allowing for preemptive monitoring and intervention.

Guideline Recommendations

Current guidelines from gastroenterological societies emphasize thorough medication review in all patients presenting with EPI. Early initiation of PERT is recommended in symptomatic individuals, with ongoing assessment of response. For oncology patients, proactive screening for DIPED is advised, particularly with agents known to affect pancreatic function. Multidisciplinary management and patient education are strongly encouraged. Guidelines also call for reporting suspected cases to pharmacovigilance agencies to enhance collective understanding and inform future recommendations.

Conclusion

Drug-induced pancreatic exocrine dysfunction is an underappreciated yet clinically impactful condition with significant implications for patient morbidity and quality of life. Vigilant recognition, mechanism-based evaluation, and prompt initiation of enzyme replacement therapy are essential to optimal outcomes. Ongoing research into diagnostics, risk stratification, and novel therapeutics holds promise for further improving care. Clinicians must maintain a high index of suspicion for DIPED in at-risk populations and adhere to evolving guideline recommendations to ensure best practices in management.